Patient-controlled Analgesic Pumps Market Size, Share & Trends Analysis Report By Type (Electronic, Mechanical), By Application (Diabetes, Oncology, Gastroenterology, Hematology), By End-use, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global patient-controlled analgesic pumps market size was valued at USD 292.4 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.6% from 2021 to 2028. The rise in the geriatric population and increasing preference for surgical procedures with technological advancements that enable procedures at the office and home care settings are the major factors driving the market. The patient-controlled pumps promote better patient management and care, thus offering several advantages in comparison to the conventional modules. In addition, rising trends of home healthcare settings due to COVID19 are expected to boost the demand for patient-controlled analgesic (PCA) pumps in near future. However, due to the restricted number of surgeries during the second and third quarters of 2020, the overall COVID19 impact on the global market caused a steep decline in the respective year. In Japan, the market is expected to regain its momentum from the second quarter of 2021 as shown in the bar graph represented below:

The prevalence of chronic disorders such as cancer, arthritis, and pain witnessed a steep rise across the globe. The growing number of individuals suffering from chronic pain will enhance the overall market growth. For instance, as per the Centers for Disease Control and Prevention (CDC), around 20.4% of adults had chronic pain across the U.S. in 2016. In addition, the occurrence of chronic pain will increase in the upcoming years owing to a rise in diabetes and a surge in cancer survival rates. This chronic pain condition requires analgesic pumps for timely pain relief, leading to an increase in demand for patient-controlled analgesic pumps.

Furthermore, rising cancer cases throughout the globe are anticipated to escalate market progression. For instance, according to the National Cancer Institute, about 1,806,590 new cancer cases were diagnosed in the U.S. in 2020. Thus, the surging prevalence of cancer creates demand for patient-controlled analgesic pumps, as they are effective and safe for relieving cancer-associated pain.

Patient-controlled analgesic pumps are widely used during post-surgical recovery as they provide consistent methods of pain management as compared to frequent analgesic injections. In addition, the PCA pump offers patients to self-administer significant doses of narcotics directly into the vein by just pressing the push button. It also aids in managing pain after undergoing surgery for faster recovery. Similarly, these pumps help in reducing or eliminating the need for intramuscular injections. It also offers decreased patient anxiety, better analgesic effects, and has substantial improvements in pulmonary complications as compared to other forms of analgesic. Thus, several advantages associated with PCA pumps include greater patient satisfaction, improved pain relief, and fewer postoperative complications, accelerating market growth.

Various patient-controlled analgesic pumps are suitable for pain management in a homecare environment, especially during the pandemic when hospital stays are reduced to the minimum. For instance, CME Medical’s TPCA Patient Controlled Analgesia Syringe Pump is useful in home care services as well as hospitals based on the patient’s needs. These pumps are compact, lightweight and are suitable for ambulatory and bedside use. Hence, increasing demand for PCA pumps in home care settings will boost market progression.

Patient-controlled analgesic pumps are useful for a variety of painful conditions and are majorly useful in acute postoperative pain management. Novel patient-controlled analgesic techniques such as PCRA, PCEA, and noninvasive forms of PCA have expanded the options for pain treatment. Additionally, advances in PCA technology including variable-rate infusions that are calculated based on patient needs for analgesia and enhanced patient monitoring will boost the use of these techniques during the forecast timeframe.

Incorporation of the newest technology in PCA pumps helps in faster pain recovery and leads to increased patient preference, thereby accelerating market growth. For instance, Acromed Chroma infusion pumps integrate the latest technology in pain control that allows patients to self-administer bolus analgesic medicine. This aids patients to control pain and allows them to feel comfortable while minimizing the need for on-site support from hospital members.

Type Insights

The electronic pumps segment dominated the market for patient-controlled analgesic pumps and accounted for the largest revenue share of 56.8% in 2020. An electronically patient-controlled analgesic pump uses a high-performance single-chip microcomputer and control circuit to effectively control the infusion flow rate. Electronic analgesic pumps are effective and safe for Patient-controlled Epidural Analgesia (PCEA) for childbirth as well as postoperative pain management, augmenting the segment demand. Additionally, studies have shown that electronic PCA pumps are suitable for a large population base, as they can be regulated based on patient’s needs. However, there are chances that several PCA treatment errors may occur in electronic PCA pumps. Human and equipment errors may occur during the dosing phase that may hamper the segmental growth over the analysis timeframe.

Mechanical is the second-largest type segment with promising growth opportunities. Mechanical patient-controlled analgesic pumps have several advantages, leading to increasing preference among healthcare professionals and patients. Advantages of mechanical PCA pumps include small size, easy portability, low price, and no programming errors. Also, several studies have shown that mechanical analgesic pumps have fewer failures and high patient satisfaction, increasing their adoption rate.

End-use Insights

The hospitals segment dominated the market for patient-controlled analgesic pumps and accounted for the largest revenue share of 31.5% in 2020. Patient-controlled analgesic therapy is most commonly used in hospital settings. Availability of most of the smart and advanced patient-controlled analgesic pumps in hospitals along with increasing demand for advanced PCA pumps in newly set up hospitals especially in developing countries is anticipated to fuel the growth of the market.

The home care settings segment is anticipated to exhibit the fastest CAGR over the forecast period. Pain-related hospitalization can be prevented, if opting for homecare settings, securing its market growth. Patient-controlled analgesic with Computerized Ambulatory Drug Delivery Device (CADD) can be used to manage pain in the home care setting. Individuals who are in hospice or have moderate to severe pain caused by cancer can use PCA pumps at home, augmenting the growth of the segment.

Application Insights

The oncology segment dominated the patient-controlled analgesic pumps market and accounted for the largest revenue share of 30.6% in 2020. PCA pumps control cancer pain by self-administration of intravenous opioids with the use of a programmable pump. Patient-controlled analgesic pumps are used at home by individuals that are suffering from moderate to severe pain from cancer. Thus, increasing usage of PCA pumps at home care settings for the treatment of diabetes is projected to enhance segmental growth. In addition, several centers such as specialty clinics, hospitals, and ambulatory surgical centers are routinely offering patient-controlled analgesic pumps for cancer suffering individuals to manage chronic pain. Thus, the increasing number of hospitals, ambulatory surgical centers, and specialty centers in developed as well as developing economies providing pain management solutions among cancer patients is estimated to boost the market growth.

The diabetes segment is likely to expand at a lucrative CAGR of 6.4% from 2021 to 2028. PCA pumps are useful in reducing pain among diabetic patients. The increasing prevalence of diabetes across the globe is expected to surge the demand for PCA pumps, fostering the growth of the segment. For instance, as per the American Diabetes Association, around 34.2 million Americans were suffering from diabetes in 2018. Patient-controlled analgesic pumps are increasingly being preferred in the management of type-1 diabetes for pain control.

Regional Insights

North America dominated the market for patient-controlled analgesic pumps and accounted for the largest revenue share of 40.0% in 2020. The region is expected to continue its dominance over the forecast period. Regionally, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. Increasing cases of diabetes, cancer, accidental injuries, and other diseases related to pain management are expected to secure the growth of the market for patient-controlled analgesic pumps. The growing geriatric population base coupled with the rising benefits of patient-controlled analgesic pumps is also contributing to the region’s development.

Asia Pacific is projected to exhibit the fastest CAGR over the forecast period. The increasing incidence of chronic diseases along with rising awareness about new technologies especially in India and China is expected to boost market expansion in the coming years. Growing geriatric population, increasing awareness about pain management, and improving healthcare facilities and infrastructure are the factors propelling the market growth.

Key Companies & Market Share Insights

Product launch, strategic acquisitions, and innovation are major strategies adopted by the key players to retain their market share. Some of the prominent players in the patient-controlled analgesic (PCA) pumps market include:

• Baxter International Inc.

• B. Braun Melsungen AG

• Smiths Group plc

• Fresenius SE & Co. KGaA

• Becton, Dickinson and Company

• ICU Medical

Patient-controlled Analgesic Pumps Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global patient-controlled analgesic pumps market report based on type, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2016 - 2028)

  • Electronic

  • Mechanical

• Application Outlook (Revenue, USD Million, 2016 - 2028)

  • Diabetes

  • Oncology

  • Gastroenterology

  • Hematology

  • Others

• End-use Outlook (Revenue, USD Million, 2016 - 2028)

  • Hospitals

  • Specialty Clinics

  • Ambulatory Surgical Centers

  • Home Care Settings

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE